Evaluate the safety, tolerability, and objective response rate (ORR) of SHR2554 tablets in combination with other anti-tumor treatments in subjects with locally advanced or metastatic non-small cell lung cancer
Age range of 18-75 years old (including both ends), gender not limited;
Patients with locally advanced unresectable or metastatic non-small cell lung cancer diagnosed by pathology
ECOG score is 0 or 1
Expected survival period ≥ 12 weeks
Having difficulty swallowing or malabsorption syndrome or any other uncontrolled gastrointestinal disease (such as nausea, diarrhea, or vomiting), having undergone gastrectomy or gastric banding surgery, etc
Symptomatic or active central nervous system tumor metastasis
Previously or simultaneously suffering from other malignant tumors
Spinal cord compression that cannot be cured by surgery and/or radiotherapy